Skip Nav Destination
Issues
1 June 2020
-
Cover Image
Cover Image
The cover shows distribution of a fluorescently labeled antibody (green) in a tumor cell nest after systemic administration (i.e., in vivo immunohistochemistry to trace drug delivery in human tumors) and illustrates that the binding-site barrier is real. For details, see the article by Lu and colleagues on page 2582 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Review
Perspectives
Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)
Martin Smoragiewicz; Alex A. Adjei; Emiliano Calvo; Josep Tabernero; Aurélien Marabelle; Christophe Massard; Jun Tang; Elisabeth G.E. de Vries; Jean-Yves Douillard; Lesley Seymour; for the task force on Methodology for the Development of Innovative Cancer Therapies
Clinical Trials: Targeted Therapy
Author Choice
BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer
Gary Middleton; Yiqun Yang; Catarina D. Campbell; Thierry André; Chloe E. Atreya; Jan H.M. Schellens; Takayuki Yoshino; Johanna C. Bendell; Antoine Hollebecque; Autumn J. McRee; Salvatore Siena; Michael S. Gordon; Josep Tabernero; Rona Yaeger; Peter J. O'Dwyer; Filip De Vos; Eric Van Cutsem; John M. Millholland; Jan C. Brase; Fatima Rangwala; Eduard Gasal; Ryan B. Corcoran
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C. Dhani; Hal W. Hirte; Lisa Wang; Julia V. Burnier; Angela Jain; Marcus O. Butler; Stephen Welch; Gini F. Fleming; Jean Hurteau; Koji Matsuo; Daniela Matei; Waldo Jimenez; Carolyn Johnston; Mihaela Cristea; Katia Tonkin; Prafull Ghatage; Stephanie Lheureux; Anjali Mehta; Judy Quintos; Qian Tan; Suzanne Kamel-Reid; Olga Ludkovski; Ming-Sound Tsao; John J. Wright; Amit M. Oza
Author Choice
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study
Wassim Abida; David Campbell; Akash Patnaik; Jeremy D. Shapiro; Brieuc Sautois; Nicholas J. Vogelzang; Eric G. Voog; Alan H. Bryce; Ray McDermott; Francesco Ricci; Julie Rowe; Jingsong Zhang; Josep Maria Piulats; Karim Fizazi; Axel S. Merseburger; Celestia S. Higano; Laurence E. Krieger; Charles J. Ryan; Felix Y. Feng; Andrew D. Simmons; Andrea Loehr; Darrin Despain; Melanie Dowson; Foad Green; Simon P. Watkins; Tony Golsorkhi; Simon Chowdhury
A Phase I Study of Safety, Pharmacokinetics, and Pharmacodynamics of Concurrent Everolimus and Buparlisib Treatment in Advanced Solid Tumors
Taofeek K. Owonikoko; R. Donald Harvey; Bradley Carthon; Zhengjia Chen; Colleen Lewis; Hanna Collins; Chao Zhang; David H. Lawson; Olatunji B. Alese; Mehmet Asim Bilen; Gabriel L. Sica; Conor E. Steuer; Walid L. Shaib; Christina Wu; Wayne B. Harris; Mehmet Akce; Ragini R. Kudchagkar; Bassel F. El-Rayes; Sagar Lonial; Suresh S. Ramalingam; Fadlo Raja Khuri
Clinical Trials: Immunotherapy
Author Choice
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Michael B. Atkins; Brian I. Rini; Robert J. Motzer; Thomas Powles; David F. McDermott; Cristina Suarez; Sergio Bracarda; Walter M. Stadler; Frede Donskov; Howard Gurney; Stephane Oudard; Motohide Uemura; Elaine T. Lam; Carsten Grüllich; Caroleen Quach; Susheela Carroll; Beiying Ding; Qian (Cindy) Zhu; Elisabeth Piault-Louis; Christina Schiff; Bernard Escudier
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer
G. Travis Clifton; Diane Hale; Timothy J. Vreeland; Annelies T. Hickerson; Jennifer K. Litton; Gheath Alatrash; Rashmi K. Murthy; Na Qiao; Anne V. Philips; Jason J. Lukas; Jarrod P. Holmes; George E. Peoples; Elizabeth A. Mittendorf
Author Choice
First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas
Ajay K. Gopal; Ronald Levy; Roch Houot; Sandip P. Patel; Leslie Popplewell; Caron Jacobson; Xinmeng J. Mu; Shibing Deng; Keith A. Ching; Ying Chen; Craig B. Davis; Bo Huang; Kolette D. Fly; Aron Thall; Adrian Woolfson; Nancy L. Bartlett
Precision Medicine and Imaging
Author Choice
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Ibiayi Dagogo-Jack; Satoshi Yoda; Jochen K. Lennerz; Adam Langenbucher; Jessica J. Lin; Marguerite M. Rooney; Kylie Prutisto-Chang; Audris Oh; Nathaniel A. Adams; Beow Y. Yeap; Emily Chin; Andrew Do; Hetal D. Marble; Sara E. Stevens; Subba R. Digumarthy; Ashish Saxena; Rebecca J. Nagy; Cyril H. Benes; Christopher G. Azzoli; Michael S. Lawrence; Justin F. Gainor; Alice T. Shaw; Aaron N. Hata
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors
Neelima Vidula; Thereasa A. Rich; Oliver Sartor; Jennifer Yen; Aaron Hardin; Tracy Nance; Michael B. Lilly; Mohammad Amin Nezami; Sandip P. Patel; Benedito A. Carneiro; Alice C. Fan; Adam M. Brufsky; Barbara A. Parker; Benjamin B. Bridges; Neeraj Agarwal; Benjamin L. Maughan; Victoria M. Raymond; Stephen R. Fairclough; Richard B. Lanman; Aditya Bardia; Massimo Cristofanilli
Author Choice
Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Heather A. Parsons; Justin Rhoades; Sarah C. Reed; Gregory Gydush; Priyanka Ram; Pedro Exman; Kan Xiong; Christopher C. Lo; Tianyu Li; Mark Fleharty; Gregory J. Kirkner; Denisse Rotem; Ofir Cohen; Fangyan Yu; Mariana Fitarelli-Kiehl; Ka Wai Leong; Melissa E. Hughes; Shoshana M. Rosenberg; Laura C. Collins; Kathy D. Miller; Brendan Blumenstiel; Lorenzo Trippa; Carrie Cibulskis; Donna S. Neuberg; Matthew DeFelice; Samuel S. Freeman; Niall J. Lennon; Nikhil Wagle; Gavin Ha; Daniel G. Stover; Atish D. Choudhury; Gad Getz; Eric P. Winer; Matthew Meyerson; Nancy U. Lin; Ian Krop; J. Christopher Love; G. Mike Makrigiorgos; Ann H. Partridge; Erica L. Mayer; Todd R. Golub; Viktor A. Adalsteinsson
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer
Romualdo Barroso-Sousa; Tanya E. Keenan; Sonia Pernas; Pedro Exman; Esha Jain; Ana C. Garrido-Castro; Melissa Hughes; Brittany Bychkovsky; Renato Umeton; Janet L. Files; Neal I. Lindeman; Laura E. MacConaill; F. Stephen Hodi; Ian E. Krop; Deborah Dillon; Eric P. Winer; Nikhil Wagle; Nancy U. Lin; Elizabeth A. Mittendorf; Eliezer M. Van Allen; Sara M. Tolaney
Predicting Therapeutic Antibody Delivery into Human Head and Neck Cancers
Guolan Lu; Shayan Fakurnejad; Brock A. Martin; Nynke S. van den Berg; Stan van Keulen; Naoki Nishio; Ashley J. Zhu; Stefania U. Chirita; Quan Zhou; Rebecca W. Gao; Christina S. Kong; Nancy Fischbein; Mrudula Penta; Alexander D. Colevas; Eben L. Rosenthal
CDKN1B Deletions are Associated with Metastasis in African American Men with Clinically Localized, Surgically Treated Prostate Cancer
Farzana A. Faisal; Sanjana Murali; Harsimar Kaur; Thiago Vidotto; Liana B. Guedes; Daniela Correia Salles; Vishal Kothari; Jeffrey J. Tosoian; Sumin Han; Daniel H. Hovelson; Kevin Hu; Daniel E. Spratt; Alexander S. Baras; Scott A. Tomlins; Edward M. Schaeffer; Tamara L. Lotan
Translational Cancer Mechanisms and Therapy
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
Gonzalo Recondo; Magda Bahcall; Liam F. Spurr; Jianwei Che; Biagio Ricciuti; Giulia C. Leonardi; Ying-Chun Lo; Yvonne Y. Li; Giuseppe Lamberti; Tom Nguyen; Marina S.D. Milan; Deepti Venkatraman; Renato Umeton; Cloud P. Paweletz; Adem Albayrak; Andrew D. Cherniack; Kristin S. Price; Stephen R. Fairclough; Mizuki Nishino; Lynette M. Sholl; Geoffrey R. Oxnard; Pasi A. Jänne; Mark M. Awad
Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma
Malte Mohme; Cecile L. Maire; Ulf Geumann; Simon Schliffke; Lasse Dührsen; Krystian Fita; Nuray Akyüz; Mascha Binder; Manfred Westphal; Christine Guenther; Katrin Lamszus; Felix G. Hermann; Nils Ole Schmidt
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Adam J. Schoenfeld; Joseph M. Chan; Daisuke Kubota; Hiroki Sato; Hira Rizvi; Yahya Daneshbod; Jason C. Chang; Paul K. Paik; Michael Offin; Maria E. Arcila; Monika A. Davare; Ujwal Shinde; Dana Pe'er; Natasha Rekhtman; Mark G. Kris; Romel Somwar; Gregory J. Riely; Marc Ladanyi; Helena A. Yu
Determining the Optimal Adjuvant Therapy for Improving Survival in Elderly Patients with Glioblastoma: A Systematic Review and Network Meta-analysis
Farshad Nassiri; Shervin Taslimi; Justin Z. Wang; Jetan H. Badhiwala; Tatyana Dalcourt; Nazanin Ijad; Neda Pirouzmand; Saleh Almenawer; Roger Stupp; Gelareh Zadeh
Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations
Zsofia Sztupinszki; Miklos Diossy; Marcin Krzystanek; Judit Borcsok; Mark M. Pomerantz; Viktoria Tisza; Sandor Spisak; Orsolya Rusz; István Csabai; Matthew L. Freedman; Zoltan Szallasi
Author Choice
Cannabinoids Promote Progression of HPV-Positive Head and Neck Squamous Cell Carcinoma via p38 MAPK Activation
Chao Liu; Sayed H. Sadat; Koji Ebisumoto; Akihiro Sakai; Bharat A. Panuganti; Shuling Ren; Yusuke Goto; Sunny Haft; Takahito Fukusumi; Mizuo Ando; Yuki Saito; Theresa Guo; Pablo Tamayo; Huwate Yeerna; William Kim; Jacqueline Hubbard; Andrew B. Sharabi; J. Silvio Gutkind; Joseph A. Califano
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
Melinda L. Telli; Charles Chu; Sunil S. Badve; Shaveta Vinayak; Daniel P. Silver; Steven J. Isakoff; Virginia Kaklamani; William Gradishar; Vered Stearns; Roisin M. Connolly; James M. Ford; Joshua J. Gruber; Sylvia Adams; Judy Garber; Nadine Tung; Chris Neff; Ryan Bernhisel; Kirsten M. Timms; Andrea L. Richardson
A Chimeric Signal Peptide–Galectin-3 Conjugate Induces Glycosylation-Dependent Cancer Cell–Specific Apoptosis
Sok-Hyong Lee; Fatima Khwaja Rehman; Kari C. Tyler; Bing Yu; Zhaobin Zhang; Satoru Osuka; Abdessamad Zerrouqi; Milota Kaluzova; Costas G. Hadjipanayis; Richard D. Cummings; Jeffrey J. Olson; Narra S. Devi; Erwin G. Van Meir
ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition
Weinan Guo; Jinyuan Ma; Yuqi Yang; Sen Guo; Weigang Zhang; Tao Zhao; Xiuli Yi; Huina Wang; Shiyu Wang; Yu Liu; Wei Dai; Xuguang Chen; Qiong Shi; Gang Wang; Tianwen Gao; Chunying Li
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds